Last $2.30 USD
Change Today -0.01 / -0.43%
Volume 523.5K
ATRS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 2:20 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

100 Princeton South

Suite 300

Ewing, NJ 08628

United States

Phone: 609-359-3020

Fax:

erapies for the prevention of blood clots and treatments for multiple sclerosis, inflammatory diseases, impotence, infertility, AIDS and hepatitis. The company’s topical oxybutynin gel 3% product for the treatment of OAB was approved by the FDA. Actavis is marketing Gelnique 3% along with Gelnique 10% with a large sales force focused on urologists. Elestrin is being marketed by Meda as an estrogen replacement gel for the treatment of hot flashes. Manufacturing The company operates under a manufacturing agreement with Minnesota Rubber and Plastics, a contract manufacturing company, who manufactures and assembles its needle-free devices and certain related disposable component parts for its partners Teva, Ferring and JCR. The company has contracted with Phillips-Medisize Corporation, an international outsource provider of design and manufacturing services, to produce clinical and commercial quantities of its Vibex QS T auto injector device and its pen injector device for an undisclosed Teva product. The company has contracted with Nypro Inc. (Nypro), an international manufacturing development company to supply commercial quantities of its Vibex pressure assisted auto injector device in compliance with FDA QSR regulations for its OTREXUP and Vibex epinephrine products. The company has contracted with Uman Pharma (Montreal, Canada) to supply commercial quantities of methotrexate pre-filled syringes for the U.S and Canadian markets for OTREXUP. The company has contracted with Sharp Corporation, an international contract packaging company, to assemble and package OTREXUP. Distribution In connection with the launch of OTREXUP, the company contracted with a third-party logistics provider, Cardinal Health 105, Inc. for key services related to logistics, warehousing and inventory management, distribution, contract administration and chargeback processing, accounts receivable management and call center management. Trade In connection with the launch of OTREXUP, the company contracted with wholesale distributors, such as McKesson, Cardinal Health 105, Inc. and Amerisource Bergen to distribute its OTREXUP product to the retail pharmacies, as well as the Veterans Administration and other governmental agencies. Sales and Marketing OTREXUP: In 2013, the company announced the approval of OTREXUP (methotrexate) injection by the FDA, and in January 2014, it announced the launch of OTREXUP. The company has worldwide marketing rights for OTREXUP and would commercialize OTREXUP on its own in the U.S. for the treatment of RA. Partnered Products Teva accounted for 66%; Ferring accounted for 19%; and Actavis accounted for 7% of the company’s worldwide revenues in 2013. Collaborative Arrangements and License Agreements The company granted an exclusive license to ANI Pharmaceuticals to develop and commercialize four of its gel technology products for use in hormone replacement therapy in North America and other countries. The company has a joint development agreement with the Population Council, an international, non-profit research organization, to develop contraceptive formulation products containing Nestorone, by using the Population Council’s patented compound and other proprietary information covering the compound, and its transdermal delivery gel. The company has a supply agreement with Teva. Pursuant to the agreement, Teva is obligated to purchase all of its delivery device requirements from it for hGH marketed in the United States. The company has a license, development and supply agreement with Teva under which it would develop and supply a disposable pen injector for use with two undisclosed patient-administered pharmaceutical products. The company has a licensing agreement with Pfizer Consumer Healthcare (Pfizer) for one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Seasonality of Business The company is subject to and affected by the business practices of its pharmaceutical/device partners. Development revenue the company derives from its partners is subject to fluctuation based on various programs being conducted by i

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRS:US $2.30 USD -0.01

ATRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biolase Inc $2.57 USD -0.05
Cerus Corp $4.53 USD +0.14
Pluristem Therapeutics Inc $2.54 USD -0.07
SurModics Inc $21.01 USD -0.42
Uroplasty Inc $2.38 USD 0.00
View Industry Companies
 

Industry Analysis

ATRS

Industry Average

Valuation ATRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.2x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTARES PHARMA INC, please visit www.antarespharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.